| __timestamp | Takeda Pharmaceutical Company Limited | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 612613000000 | 7751000 |
| Thursday, January 1, 2015 | 650773000000 | 10251000 |
| Friday, January 1, 2016 | 619061000000 | 9575000 |
| Sunday, January 1, 2017 | 628106000000 | 10912000 |
| Monday, January 1, 2018 | 717599000000 | 11049000 |
| Tuesday, January 1, 2019 | 964737000000 | 11646000 |
| Wednesday, January 1, 2020 | 875663000000 | 13265000 |
| Friday, January 1, 2021 | 886361000000 | 25805000 |
| Saturday, January 1, 2022 | 997309000000 | 35182000 |
| Sunday, January 1, 2023 | 1053819000000 | 94999000 |
| Monday, January 1, 2024 | 1053819000000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants and emerging players is crucial. Takeda Pharmaceutical Company Limited, a global leader, has consistently demonstrated robust financial management. From 2014 to 2023, Takeda's Selling, General, and Administrative (SG&A) expenses have shown a steady upward trend, peaking at approximately 1.05 trillion yen in 2023, marking a 72% increase over the decade.
In contrast, Viridian Therapeutics, Inc., a smaller yet ambitious player, has seen its SG&A expenses grow from 7.75 million dollars in 2014 to nearly 95 million dollars in 2023. This represents a staggering 1,126% increase, reflecting its aggressive expansion and investment in growth.
While Takeda's expenses highlight its stable market position, Viridian's rapid increase underscores its dynamic growth strategy. The absence of data for 2024 suggests a potential shift or recalibration in Viridian's financial approach.
Cost Management Insights: SG&A Expenses for Novartis AG and Viridian Therapeutics, Inc.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Viridian Therapeutics, Inc.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Mesoblast Limited Trends and Insights
Takeda Pharmaceutical Company Limited or Viridian Therapeutics, Inc.: Who Invests More in Innovation?
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Viridian Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Soleno Therapeutics, Inc. or Viridian Therapeutics, Inc.